The complexity of producing GLP-1 drugs, which often come in injectable pen formats, has added further delays
The dose can be further be increased every month, up to a maximum dose
Moreover, null or inconsistent findings in some mechanistic trials, including absent changes in certain satiety hormones or mixed reward-response patterns, underscore the complexity of these pathways
Patients With Established Cardiovascular Disease Injectable semaglutide currently has more mature cardiovascular outcome data
Weight regain following weight loss, however that weight loss is achieved, is common
Industry experts consider Retatrutide one of the most anticipated obesity therapies expected to shape the future of weight management globally